HAPPY SATURDAY TO THE STREET
And welcome back to Street Tweets from The Street Sheet!
The economy has a great résumé.
It just has a terrible attitude.
Consumer sentiment slid to 46.3 in early October, within two points of the all-time low it hit in May.
That's with weekly jobless claims still sitting below 200K.
So Americans have the jobs. They just can't stand what the paycheck buys.
Call it a vibecession.
The jobs are in stock. The joy is on back order.
— Brooks & The Street Sheet Team
MARKET REVIEW & PREVIEW
Wall Street flipped the script on the Fed last week. A weaker-than-expected September jobs report and word that the US has no plans for further strikes on Iran sent traders backing away from bets on an October rate hike. The S&P 500 climbed a little more than 1%, with the Dow close behind.
Presented by Street Sheet Research
Ozempic helped push Novo Nordisk (NVO) to a valuation of more than $500B. That was bigger than the entire economy of Denmark, the company's home country.
Now a stronger treatment is on the way, one the financial press already calls potentially the most powerful weight loss drug yet. And with roughly 31M Americans having already tried GLP-1s, tens of millions more haven't started.
We're naming the company behind it in this week's report.
Backed by a 90-day money-back guarantee.
Growth stock behavior.
Every hour the AI agent saves gets reinvested in more work, and not one gets paid out as a dividend.
Profit on paper, cash out the door.
With Big Tech spending $700B+ on capex this year, earnings are an opinion, and cash is a fact.
Presented by Street Sheet Research
A breakthrough drug is only half the setup. The other half is a Wall Street that keeps underestimating the company behind it.
Trial-tested results: patients lost up to 30% of their body weight in late-stage trials, vs roughly 15% to 20% for today's leading treatments.
Serial estimate beats: the company topped Wall Street's earnings estimates in each of the last four quarters, by 26% and 27% in the two most recent.
Rising forecasts: two analysts lifted their outlooks in the past week alone, ahead of earnings later this month.
Blockbuster potential: MarketBeat thinks the new drug could become the biggest blockbuster in history.
The name is inside this week's report, while the window is still open.
90-day money-back guarantee. Cancel anytime.
Congrats on your new landlord.
Of today’s record $2,398 payment, $2,143 goes to the bank, and just $255 goes to the house.
